An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)

#1684

Introduction: In ELECT, LAN 120mg every 4 weeks significantly reduced octreotide rescue therapy use for symptomatic CS control vs placebo (PBO).

Aim(s): This patient centric analysis explores the treatment effect on patient benefit during this trial.

Materials and methods: The analysis used all patient-reported outcomes collected during the double-blind phase of ELECT: daily diarrhea and flushing symptoms, octreotide rescue use and EORTC QLQ-C30 and QLQ-GINET.21 questionnaires at baseline and week 12. We applied principal component (PC) analysis on the baseline data to identify independent variable clusters, identified summary measures that were highly correlated to these PCs, derived minimum clinical important differences (MCID) and performed a responder analysis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Duchateau L

Authors: Duchateau L, Lescrauwaet B, Blot K, Liyanage N, Ray D,

Keywords: SSA, carcinoid, symptoms,